ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
02/04/201608:00:00FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) fo...
02/03/201616:13:00Merck Posts Lower Revenue and Profit -- 2nd Update
02/03/201616:09:00Correction to Merck Earnings Story
02/03/201613:08:00Merck Revenue and Profit Falls -- Update
02/03/201608:30:00Merck Revenue and Profit Falls
02/03/201608:21:00Merck Revenue and Profit Falls
02/03/201606:57:37Current Report Filing (8-k)
02/03/201606:45:00Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
01/28/201621:36:00FDA Approves Merck's New Hepatitis C Treatment -- 2nd Update
01/28/201620:15:00FDA Approves Merck's New Hepatitis C Treatment -- Update
01/28/201619:10:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) f...
01/28/201618:59:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir & grazoprevir) f...
01/27/201613:49:00FDA to Review Merck Antitoxin for Clostridium Difficile
01/27/201608:30:00Merck Announces FDA Acceptance of Biologics License Application...
01/25/201605:00:00Affimed Enters into Collaboration with Merck to Evaluate AFM13...
01/19/201610:00:00Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal...
01/17/201621:30:00Samsung Gets European Approval for Enbrel Copy
01/16/201603:02:00Merck Pays $830 Million To Settle Suit Over Vioxx Claims

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad